Catarina Reis Santos

Dr. Catarina Reis Santos

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in BMC Obesity
Verified
Journal Article
Open access
PDF file
CSCatarina Reis Santos
Catarina Reis Santos
PSPedro Marques da Silva
Pedro Marques da Silva
Obesity is a well-known condition of resistant hypertension (HT). Insights to the hemodynamic patterns that characterize obesity related hypertension may help guide therapeutic adjustments and shorten time to HT control. We performed a retrospective analysis of 202 patients followed at our Hypertension Clinic with the diagnosis of primary HT and who performed an impedance cardiography (ICG) test. Obtained data was analyzed to identify differences between obese and non-obese patients and to identify predictors of uncontrolled HT (≥ 140 and/or ≥ 90 mmHg) in obese patients. One hundred patients were male (49.5%) and average age 54.6 ± 13.9 years. Average systolic and diastolic pressures were 136.5 ± 22.4 mmHg and 82.9 ± 5.1 mmHg, respectively. The average BMI was 28.9 ± 5.1 Kg/m2. Seventy one patients (35.1%) had systolic arterial pressure (AP) ≥140 mmHg and 45 patients (22.3%) diastolic AP ≥90 mmHg. BMI correlated with systolic and diastolic AP (Pearson’s coefficient 0.235; p < 0.001 and 0.163; p < 0.001, respectively). Obese patients presented increased cardiac index (CI) (p < 0.001), left cardiac work index (LCWI) (p < 0.001) and systemic vascular resistance index (SVRI) (p < 0.001) but reduced systemic arterial compliance index (SACI) (p < 0.001). Obese patients with uncontrolled HT had greater BMI (p < 0.001), CI (p < 0.001) and SVRI (p < 0.001) but lower SACI (p < 0.001) and LCWI (p < 0.001). In multivariate analysis, however, only CI remained predictive, conferring a risk 1.47 higher of uncontrolled HT. Obese patients, including those with uncontrolled HT, had increased CI and SVRI. The only predictor of uncontrolled HT, however, was CI, suggesting that the obese present a state of hyperinotropy and may benefit of “add-on” or increase treatment with beta-blockers.

Verified
Journal Article
Open access
PDF file
CSCatarina Reis Santos
Catarina Reis Santos
RCRui Carvalho
Rui Carvalho
A. Mafalda FonsecaA. Mafalda Fonseca
A. Mafalda Fonseca
MCMiguel Castelo-Branco
Miguel Castelo-Branco
Marco AlvesMarco Alves
Marco Alves
Ivana JarakIvana Jarak
Ivana Jarak
In arterial hypertension, the dysregulation of several metabolic pathways is closely associated with chronic immune imbalance and inflammation progression. With time, these disturbances lead to the development of progressive disease and end-organ involvement. However, the influence of cholecalciferol on metabolic pathways as a possible mechanism of its immunomodulatory activity in obesity-related hypertension is not known. In a phase 2, randomized, single-center, 24-week trial, we evaluated, as a secondary outcome, the serum metabolome of 36 age- and gender-matched adults with obesity-related hypertension and vitamin D deficiency, before and after supplementation with cholecalciferol therapy along with routine medication. The defined endpoint was the assessment of circulating metabolites using a nuclear magnetic resonance-based metabolomics approach. Univariate and multivariate analyses were used to evaluate the systemic metabolic alterations caused by cholecalciferol. In comparison with normotensive controls, hypertensive patients presented overall decreased expression of several amino acids (p < 0.05), including amino acids with ketogenic and glucogenic properties as well as aromatic amino acids. Following cholecalciferol supplementation, increases were observed in glutamine (p < 0.001) and histidine levels (p < 0.05), with several other amino acids remaining unaffected. Glucose (p < 0.05) and acetate (p < 0.05) decreased after 24 weeks in the group taking the supplement, and changes in the saturation of fatty acids (p < 0.05) were also observed, suggesting a role of liposoluble vitamin D in lipid metabolism. Long-term cholecalciferol supplementation in chronically obese and overweight hypertensives induced changes in the blood serum metabolome, which reflected systemic metabolism and may have fostered a new microenvironment for cell proliferation and biology. Of note, the increased availability of glutamine may be relevant for the proliferation of different T-cell subsets.

25 January 2023 in Clinical Immunology
Verified
Journal Article
Open access
CSCatarina Reis Santos
Catarina Reis Santos
AMAndreia Monteiro
Andreia Monteiro
RRRicardo Rodrigues
Ricardo Rodrigues
CFCatarina Ferreira
Catarina Ferreira
JCJoana Coutinho
Joana Coutinho
A. Mafalda FonsecaA. Mafalda Fonseca
A. Mafalda Fonseca
In arterial hypertension, increased Th17 cells and reduced Tregs are the hallmarks of immunological dysfunction and the basis for the investigation of immunomodulatory drugs. Although cholecalciferol is not a primary immunomodulator, it has recognized action on immune cells, leading us to hypothesise if cholecalciferol can induce a more tolerogenic phenotype in obese hypertensives. In a phase-2, single-centre, randomised, open, 24-week trial, we assigned adults with obesity-associated hypertension and vitamin D deficiency to receive usual therapy plus 50,000 IU/week of cholecalciferol or usual therapy alone. The primary endpoint was the percentual variation in T CD4+, T CD8+, Tregs, and Th17 cells. Secondary endpoints included the percentual variation in Th1, Tc1, Tc17, and monocytes and variation in the number of perivascular and non-perivascular macrophages, T CD4+ and T CD8+ lymphocytes in subcutaneous abdominal adipose tissue. A control group of 12 overweight normotensives was also evaluated for peripheral immune cells. A total of 36 obese hypertensives were randomised, 18 in each group. In comparison with normotensive controls, hypertensives presented higher percentages of T lymphocytes (p = 0.016), Tregs (p = 0.014), and non-classical monocytes (p < 0.001). At week 24, Th17 cells increased in control group (p = 0.017) but remained stable in cholecalciferol group. For Tregs, downregulation towards the values of normotensive controls was observed (p = 0.003), and in multivariate analysis, an increased loading in the setting of the cells of adaptive immunity observed (eigenvalue 1.78, p < 0.001). No changes were documented for monocytes. In adipose tissue, a baseline negative correlation between vitamin D and perivascular macrophages was observed (r = -0.387, p = 0.024) that persisted in the control group (r = -0.528, p = 0.024) but not in the cholecalciferol group, which presented an increase in non-perivascular macrophages (p = 0.029) at week 24. No serious adverse events were reported for all the participants. In this trial, we found that supplementation with cholecalciferol interfered with peripheral and adipose tissue immune cell profile, downregulating peripheral Th17 cells, but increasing the number of infiltrating subcutaneous adipose tissue macrophages. (Funded by Núcleo Estudos Hipertensão da Beira Interior; EudraCT number: 2015-003910-26).

26 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
IBInês Barreto
Inês Barreto
AMAndreia Monteiro
Andreia Monteiro
ERErnesto Fernandes Rocha
Ernesto Fernandes Rocha
CSCatarina Reis Santos
Catarina Reis Santos
A. Mafalda FonsecaA. Mafalda Fonseca
A. Mafalda Fonseca
Introduction: Patients undergoing hemodialysis (HD) often exhibit an impaired cellular immune response, which may contribute to an increased susceptibility to infections and other complications. Th1 cells, a subset of T-helper cells, play a crucial role in cellular immunity. However, the modulation of Th1 cells by HD treatment remains unclear. Objective: This study aims to investigate the levels of circulating T cells, especially Th1 cells, and the neutrophil-to-lymphocyte ratio (NLR) in HD patients. Methods: We recruited 26 HD patients and 10 healthy volunteers. Demographical data were collected, and peripheral blood samples were analyzed. Absolute blood cell counts were determined, and T-cell populations were identified using flow cytometry. Th1 cells were defined as IFN-γ-producing CD4+ T cells after in vitro activation, and NLR was calculated through the ratio between the neutrophil and lymphocyte counts measured in peripheral blood. Results: We have observed a significant decrease in Th1 subpopulation frequency in HD patients, as well as significant correlations between immunological and demographic parameters, among which are the NLR values and the absolute values of T-cell subsets. Conclusions: These results seem to clarify the role of Th1 cells in modulating the immune responses of hemodialysis-treated patients, potentially considering its frequency as an indicator for CKD development.

1 January 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
LRLígia Ribeiro
Lígia Ribeiro
MPMicael Pompermayer
Micael Pompermayer
CSCatarina Reis Santos
Catarina Reis Santos
JCJoana Coutinho
Joana Coutinho
Gitelman syndrome (GS) is an inherited salt-wasting, hypokalemic tubulopathy caused mainly by biallelic loss-of-function variants in the SLC12A3 gene. Despite being classically diagnosed in adolescence, delayed recognition may occur. We present the case of a 74-year-old man with a history of hypokalemia, in whom the diagnostic evaluation revealed hypokalemia, hypomagnesemia, metabolic alkalosis, hypocalciuria, and secondary hyperreninemic hyperaldosteronism, consistent with renal potassium wasting. Given the late presentation, the main challenge was the need to distinguish an inherited tubulopathy from common acquired causes of hypokalemia. Genetic testing was performed, identifying a previously unreported homozygous out-of-frame deletion in exon 25 of the SLC12A3 gene, predicted to result in loss of protein function and therefore to be pathogenic. Treatment with supplementation plus spironolactone achieved sustained biochemical improvement and clinical stability during long-term follow-up. This case highlights that GS should be considered in patients with chronic unexplained hypokalemia regardless of age, and that genetic testing is essential for definitive diagnosis.

1 January 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
LRLígia Ribeiro
Lígia Ribeiro
MPMicael Pompermayer
Micael Pompermayer
CSCatarina Reis Santos
Catarina Reis Santos
JCJoana Coutinho
Joana Coutinho
RESUMO A síndrome de Gitelman (SG) é uma tubulopatia hereditária, perdedora de sal e hipocalêmica, causada sobretudo por variantes bialélicas com perda de função no gene SLC12A3. Apesar de ser classicamente diagnosticada na adolescência, seu reconhecimento pode ser tardio. Apresentamos o caso de um homem de 74 anos com antecedentes de hipocalemia, cuja avaliação diagnóstica revelou hipocalemia, hipomagnesemia, alcalose metabólica, hipocalciúria e hiperaldosteronismo hiperreninêmico secundário, compatíveis com perda renal de potássio. Dada a apresentação tardia, o principal desafio foi a necessidade de distinguir uma tubulopatia hereditária das causas adquiridas comuns de hipocalemia. Foi realizado teste genético, que identificou uma deleção homozigótica com desvio do quadro de leitura (out-of-frame), até então não descrita, no éxon 25 do gene SLC12A3, prevendo-se que resulte em perda de função da proteína e, portanto, seja patogênica. O tratamento com suplementação associada à espironolactona permitiu melhoria bioquímica sustentada e estabilidade clínica durante o seguimento a longo prazo. Este caso realça que a SG deve ser considerada em pacientes com hipocalemia crônica inexplicada, independentemente da idade, e que o teste genético é essencial para o diagnóstico definitivo.